{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:56:55Z","timestamp":1758635815478,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.therap.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T21:57:49Z","timestamp":1533247069000},"page":"369-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association illogique nalm\u00e9f\u00e8ne et opio\u00efdes\u00a0: analyse dans la base fran\u00e7aise de pharmacovigilance"],"prefix":"10.1016","volume":"74","author":[{"given":"Sylvie","family":"Favreli\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Lafay-Chebassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fauconneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Quillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lissa","family":"Y\u00e9l\u00e9h\u00e9-Okouma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"P\u00e9rault-Pochat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Global status report on alcohol and health","author":"World health organization (WHO)","key":"10.1016\/j.therap.2018.06.004_bib0110"},{"year":"2013","series-title":"Selincro (nalmefene): EU summary of product characteristics","author":"European medicines agency","key":"10.1016\/j.therap.2018.06.004_bib0115"},{"issue":"2","key":"10.1016\/j.therap.2018.06.004_bib0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000363232","article-title":"Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment","volume":"21","author":"Soyka","year":"2015","journal-title":"Eur Addict Res"},{"issue":"2","key":"10.1016\/j.therap.2018.06.004_bib0125","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jsat.2010.05.008","article-title":"Comparison of opiate-primary treatment seekers with or without alcohol use disorder","volume":"39","author":"Hartzler","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.therap.2018.06.004_bib0130","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajem.2009.07.007","article-title":"First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction","volume":"28","author":"Lemesle","year":"2010","journal-title":"Am J Emerg Med"},{"year":"2010","series-title":"Compte-rendu de la r\u00e9union du 25\u00a0mai 2010. Suivi national de la m\u00e9thadone AP\u2013HP g\u00e9lule et sirop","author":"Commission nationale de pharmacovigilance","key":"10.1016\/j.therap.2018.06.004_bib0135"},{"issue":"6","key":"10.1016\/j.therap.2018.06.004_bib0140","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2515\/therapie\/2011072","article-title":"Naltrexone et traitement substitutif aux opiac\u00e9s","volume":"66","author":"Dupouy","year":"2011","journal-title":"Therapie"},{"year":"2011","series-title":"S\u00e9ance du 21\u00a0juillet 2011","author":"Commission d\u2019AMM","key":"10.1016\/j.therap.2018.06.004_bib0145"},{"year":"2011","series-title":"S\u00e9ance du 9\u00a0juin 2011","author":"Commission d\u2019AMM","key":"10.1016\/j.therap.2018.06.004_bib0150"},{"key":"10.1016\/j.therap.2018.06.004_bib0155","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00228-015-1931-y","article-title":"Withdrawal syndrome after co-medication of opioid maintenance therapy with nalm\u00e9f\u00e8ne: unrecognized interaction","volume":"71","author":"Diot","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"year":"2015","series-title":"Scientific conclusions and grounds recommending the variation to the terms of the marketing autorisation(s) of nalmefene. Procedure No. EMEA\/H\/C\/PSUSA\/00010120\/201408","key":"10.1016\/j.therap.2018.06.004_bib0160"},{"issue":"1","key":"10.1016\/j.therap.2018.06.004_bib0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/JCP.0000000000000448","article-title":"Nalmefene mistakenly prescribed to reduce alcohol consumption in patients under buprenorphine substitution therapy resulting in acute opioid withdrawal: management in an emergency setting","volume":"36","author":"P\u00e9lissier","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.therap.2018.06.004_bib0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/fcp.12286","article-title":"Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case of series of patients in Lorraine","volume":"31","author":"Yelehe-Okouma","year":"2017","journal-title":"Fund Clin Pharmacol"},{"year":"2015","series-title":"CT Pharmacovigilance du 15\/12\/2015-compte-rendu CT012015113-ANSM","key":"10.1016\/j.therap.2018.06.004_bib0175"},{"year":"2018","series-title":"Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) of nalm\u00e9f\u00e8ne. Procedure No. EMEA\/H\/C\/PSUSA\/00010120\/201602","key":"10.1016\/j.therap.2018.06.004_bib0180"},{"year":"2017","series-title":"CT Pharmacovigilance du 21\/02\/2017-compte rendu CT012017023\u2013ANSM","key":"10.1016\/j.therap.2018.06.004_bib0185"},{"issue":"8463","key":"10.1016\/j.therap.2018.06.004_bib0190","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(85)90918-3","article-title":"Adverse drug reaction monitoring: doing it the French way","volume":"2","author":"Moore","year":"1985","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.therap.2018.06.004_bib0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"year":"2018","series-title":"Code de la Sant\u00e9 publique D\u00e9cret no\u00a02012-1244\u00a0du 8\u00a0novembre 2012. Version consolid\u00e9e","key":"10.1016\/j.therap.2018.06.004_bib0200"},{"issue":"6","key":"10.1016\/j.therap.2018.06.004_bib0205","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2515\/therapie\/2008062","article-title":"Un exemple de compl\u00e9mentarit\u00e9 entre l\u2019\u00e9valuation des Centres R\u00e9gionaux de Pharmacovigilance (CRPV) et celle des Centres d\u2019Evaluation de Pharmacod\u00e9pendance (CEIP)","volume":"63","author":"Victorri-Vigneau","year":"2006","journal-title":"Therapie"},{"year":"2015","series-title":"Bulletin des vigilances","author":"ANSM","key":"10.1016\/j.therap.2018.06.004_bib0105"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595718301288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:52:38Z","timestamp":1758567158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595718301288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0040595718301288"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.06.004","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association illogique nalm\u00e9f\u00e8ne et opio\u00efdes\u00a0: analyse dans la base fran\u00e7aise de pharmacovigilance","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}